Home
Clinical Resources Search
PQI: Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

Download PQI pdf 0.27MB

Last Updated: May 5, 2025

By: Tara Graff, DO, MS

About this PQI

The purpose of this PQI is to assess an unmet need in the DLBCL patient population by enhancing the ability to evaluate treatment efficacy, monitor disease kinetics and remission, and detect early relapse.

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action Treatment Support Kit Diffuse Large B-Cell Lymphoma (DLBCL) Minimal Risidual Disease (MRD)

PQI

Frequently Searched

Supported by

Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

About this PQI

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer

PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol

PQI: Encorafenib (Braftovi®) and Binimetinib (Mektovi®) for the Management of NSCLC

PQI: Bone Health and the Cancer Patient

PQI in Action: Fruquintinib (Fruzaqla®)

PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2

PQI in Action: Proactive Symptom Management in Myelofibrosis

PQI in Action: Sonidegib (Odomzo®) Patient Management

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

PQI: Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

PQI: Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PQI: Selinexor (Xpovio®) Patient Management

PQI: Loncastuximab tesirine-lpyl (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma

PQI: clonoSEQ® Next Generation Sequencing for Minimum Residual Disease Testing in Chronic Lymphocytic Leukemia

PQI: clonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma

PQI in Action: ClonoSEQ® Next Generation Sequencing for Minimal Residual Disease Testing in Multiple Myeloma

PQI: Zanidatamab-hrii (Ziihera) for the Management of Biliary Tract Cancer

Up Close with Linvoseltamab

PQI in Action: Fruquintinib (Fruzaqla®)

PQI: Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol